^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mipasetamab uzoptirine (ADCT-601)

    i
    Other names: ADCT-601, ADCT 601, BGB601
    Company:
    Overland ADCT BioPharma
    Drug class:
    DNA replication inhibitor, AXL-targeted antibody-drug conjugate
    Related drugs:
    15d
    ADCT-601-102: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, ADC Therapeutics S.A. | N=196 --> 260
    Enrollment change • Combination therapy • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    5ms
    ADCT-601-102: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=196, Recruiting, ADC Therapeutics S.A. | Phase classification: P1b --> P1
    Phase classification
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    7ms
    ADCT-601-102: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1b, N=196, Recruiting, ADC Therapeutics S.A. | N=66 --> 196
    Enrollment change • Combination therapy • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    9ms
    PRE-CLINICAL ACTIVITY OF ADCT-601, AN ANTIBODY-DRUG CONJUGATE TARGETING AXL IN SOFT-TISSUE SARCOMA (CTOS 2023)
    No abstract available
    Preclinical
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    mipasetamab uzoptirine (ADCT-601)
    over1year
    Ultrasound-induced cavitation enhances therapeutic efficacy of AXL-targeting ADC leading to improved survival in a human xenograft model of renal cancer. (AACR-NCI-EORTC 2022)
    The purpose of this study was to test a suboptimal single dose of mipasetamab uzoptirine (ADCT-601), an ADC targeting the AXL protein, in combination with ultrasound-induced cavitation in a preclinical mouse model of renal cancer...This was demonstrated for a suboptimal ADC dose, indicating that ultrasound-mediated drug delivery could be used to reduce the administered dose while preserving therapeutic efficacy. These preclinical data warrant further evaluation of this promising combination in the clinic.
    Preclinical
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    mipasetamab uzoptirine (ADCT-601)
    almost2years
    ADCT-601-102: A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1b, N=66, Recruiting, ADC Therapeutics S.A. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    almost2years
    A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (clinicaltrials.gov)
    P1b, N=66, Not yet recruiting, ADC Therapeutics S.A.
    New P1 trial • Combination therapy
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    gemcitabine • mipasetamab uzoptirine (ADCT-601)
    2years
    Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. (PubMed, Mol Cancer Ther)
    Notably, ADCT-601 had antitumor activity in a monomethyl auristatin E-resistant lung-cancer model and synergized with the PARP inhibitor olaparib in a BRCA1-mutated ovarian cancer model. ADCT-601 was well tolerated at doses of up to 6 mg/kg and showed excellent stability in vivo. These preclinical results warrant further evaluation of ADCT-601 in the clinic.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • AXL (AXL Receptor Tyrosine Kinase)
    |
    BRCA1 mutation • AXL expression
    |
    Lynparza (olaparib) • mipasetamab uzoptirine (ADCT-601)
    2years
    AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601) (AACR 2022)
    This study demonstrated that ADCT-601 induced a potent and specific in vitro and in-vivo anti-tumor activities in AXL expressing ACC models and suggests further development of ADCT-601 in biomarker driven clinical trials.
    Preclinical • Late-breaking abstract
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    AXL expression • AXL-L
    |
    mipasetamab uzoptirine (ADCT-601)
    over4years
    Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=75, Suspended, ADC Therapeutics S.A. | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ER negative
    |
    mipasetamab uzoptirine (ADCT-601)